FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296807755> ?p ?o ?g. }

• W4296807755 endingPage "545" @default.
• W4296807755 startingPage "535" @default.
• W4296807755 abstract "To compare the treatment efficacy and safety of tyrosine kinase inhibitors (TKIs) and anti-programmed cell death 1 (PD-1) immunotherapy combined with transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC) for patients with unresectable intrahepatic cholangiocarcinoma (ICC).Patients with unresectable ICC received TKIs and anti-PD-1 immunotherapy combined with HAIC (HTP group) or TACE (TTP group) were included. The clinicopathological characteristics, treatment efficacy, and adverse events (AEs) were compared between the two groups. The factors associated with response rate to the treatments were evaluated.A total of 58 patients were enrolled, with 39 in the HTP group and 19 in the TTP group. Patients in the HTP group exhibited a better objective response rate (ORR; Response Evaluation Criteria in Solid Tumors [RECIST] 48.7% vs 15.8%, P = 0.02; modified RECIST [mRECIST] 61.5% vs 21.1%, P = 0.004) and disease control rate (DCR; 82.1% vs 36.8%, P = 0.001) compared to the TTP group. The median progression-free survival (PFS) rate was not reached and the 1-year PFS rate was 61.9% in the HTP group, whereas the median PFS was 11.0 months and the 1-year PFS rate was 31.6% in the TTP group. The type of treatment and tumor size were significant factors for the response rate. More patients in the HTP group presented rash, abdominal pain and hand-foot syndrome, but all AEs were relieved after symptomatic treatment, and no treatment-related death occurred.For unresectable ICC, treatment with a combination of HAIC with TKIs and anti-PD-1 immunotherapy was effective and safe. Tumor size might serve as a significant factor for the response rate following treatment for unresectable ICC." @default.
• W4296807755 created "2022-09-24" @default.
• W4296807755 creator A5004005650 @default.
• W4296807755 creator A5017683443 @default.
• W4296807755 creator A5018459204 @default.
• W4296807755 creator A5029484872 @default.
• W4296807755 creator A5030488028 @default.
• W4296807755 creator A5038584729 @default.
• W4296807755 creator A5039264661 @default.
• W4296807755 creator A5054418515 @default.
• W4296807755 creator A5061082958 @default.
• W4296807755 creator A5090826689 @default.
• W4296807755 date "2022-08-01" @default.
• W4296807755 modified "2023-09-26" @default.
• W4296807755 title "Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti‐ <scp>PD</scp> ‐1 immunotherapy for unresectable intrahepatic cholangiocarcinoma" @default.
• W4296807755 cites W1176097286 @default.
• W4296807755 cites W1604905924 @default.
• W4296807755 cites W1942118595 @default.
• W4296807755 cites W1966709946 @default.
• W4296807755 cites W1980980429 @default.
• W4296807755 cites W1982336985 @default.
• W4296807755 cites W2019607817 @default.
• W4296807755 cites W2068222332 @default.
• W4296807755 cites W2115261608 @default.
• W4296807755 cites W2164507773 @default.
• W4296807755 cites W2168106806 @default.
• W4296807755 cites W2208538179 @default.
• W4296807755 cites W2562671506 @default.
• W4296807755 cites W2789920308 @default.
• W4296807755 cites W2797110923 @default.
• W4296807755 cites W2949125167 @default.
• W4296807755 cites W2959525851 @default.
• W4296807755 cites W2982321050 @default.
• W4296807755 cites W2982406244 @default.
• W4296807755 cites W2999959056 @default.
• W4296807755 cites W3000125713 @default.
• W4296807755 cites W3000723598 @default.
• W4296807755 cites W3001975949 @default.
• W4296807755 cites W3008414152 @default.
• W4296807755 cites W3096339202 @default.
• W4296807755 cites W3121807241 @default.
• W4296807755 cites W3134304235 @default.
• W4296807755 cites W3134644767 @default.
• W4296807755 cites W3135697012 @default.
• W4296807755 cites W3137254944 @default.
• W4296807755 cites W3137490587 @default.
• W4296807755 cites W3144238580 @default.
• W4296807755 cites W3165575280 @default.
• W4296807755 cites W3167419679 @default.
• W4296807755 cites W4220981238 @default.
• W4296807755 cites W4280517280 @default.
• W4296807755 doi "https://doi.org/10.1111/1751-2980.13127" @default.
• W4296807755 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36148493" @default.
• W4296807755 hasPublicationYear "2022" @default.
• W4296807755 type Work @default.
• W4296807755 citedByCount "4" @default.
• W4296807755 countsByYear W42968077552023 @default.
• W4296807755 crossrefType "journal-article" @default.
• W4296807755 hasAuthorship W4296807755A5004005650 @default.
• W4296807755 hasAuthorship W4296807755A5017683443 @default.
• W4296807755 hasAuthorship W4296807755A5018459204 @default.
• W4296807755 hasAuthorship W4296807755A5029484872 @default.
• W4296807755 hasAuthorship W4296807755A5030488028 @default.
• W4296807755 hasAuthorship W4296807755A5038584729 @default.
• W4296807755 hasAuthorship W4296807755A5039264661 @default.
• W4296807755 hasAuthorship W4296807755A5054418515 @default.
• W4296807755 hasAuthorship W4296807755A5061082958 @default.
• W4296807755 hasAuthorship W4296807755A5090826689 @default.
• W4296807755 hasConcept C121608353 @default.
• W4296807755 hasConcept C126322002 @default.
• W4296807755 hasConcept C141071460 @default.
• W4296807755 hasConcept C197934379 @default.
• W4296807755 hasConcept C2776283816 @default.
• W4296807755 hasConcept C2776694085 @default.
• W4296807755 hasConcept C2777701055 @default.
• W4296807755 hasConcept C2778375690 @default.
• W4296807755 hasConcept C2778570526 @default.
• W4296807755 hasConcept C2778822529 @default.
• W4296807755 hasConcept C2779984678 @default.
• W4296807755 hasConcept C2780739268 @default.
• W4296807755 hasConcept C2909135397 @default.
• W4296807755 hasConcept C71924100 @default.
• W4296807755 hasConcept C90924648 @default.
• W4296807755 hasConceptScore W4296807755C121608353 @default.
• W4296807755 hasConceptScore W4296807755C126322002 @default.
• W4296807755 hasConceptScore W4296807755C141071460 @default.
• W4296807755 hasConceptScore W4296807755C197934379 @default.
• W4296807755 hasConceptScore W4296807755C2776283816 @default.
• W4296807755 hasConceptScore W4296807755C2776694085 @default.
• W4296807755 hasConceptScore W4296807755C2777701055 @default.
• W4296807755 hasConceptScore W4296807755C2778375690 @default.
• W4296807755 hasConceptScore W4296807755C2778570526 @default.
• W4296807755 hasConceptScore W4296807755C2778822529 @default.
• W4296807755 hasConceptScore W4296807755C2779984678 @default.
• W4296807755 hasConceptScore W4296807755C2780739268 @default.
• W4296807755 hasConceptScore W4296807755C2909135397 @default.
• W4296807755 hasConceptScore W4296807755C71924100 @default.
• W4296807755 hasConceptScore W4296807755C90924648 @default.

• next